No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 40 of the 40 quarters in the window, leaving 0 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 93.6x · 10Y median 105.1x · 39th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T19:01:14.082Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for CervoMed Inc. (CRVO) stock was $3.26 as of Oct 6, 2026, 2:59 PM EDT, down 1.51% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -61.4% · 3-year avg -14.5%/yr · 5-year avg -38.3%/yr
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a.
Biotechnology · Boston, MA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.61
Revenue Est.
$50000.00
Last Quarter Results
EPS
$-0.64
vs Estimate
$-0.86
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CRVO | $30.18M | $3.26 | -1.51% | -61.36% | -38.25% | -53.96% | N/A |
| 2MIRA | $30.18M | $0.72 | -2.35% | -45.36% | N/A | N/A | vs CRVO |
| 3GRDX | $29.88M | $4.19 | +9.40% | -11.92% | -83.84% | N/A | vs CRVO |
| 4CNTX | $29.85M | $0.32 | -3.45% | -69.24% | N/A | N/A | vs CRVO |
| 5SCYX | $30.63M | $4.87 | -3.18% | -21.32% | -34.13% | -35.18% | vs CRVO |
| 6QUCY | $29.71M | $1.30 | -3.33% | N/A | N/A | N/A | vs CRVO |
N/A
$0.00
vs Estimate
$50000.00
Consensus Rating
Based on 5 analysts
Average Price Target
$15.40
+372.4% upside
Low
$7.00
Current
$3.26
High
$25.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.59 | $-0.49 | $-0.39 | 3 |
| Quarter ending Dec 2026 | $-0.53 | $-0.45 | $-0.34 | 3 |
| Quarter ending Mar 2027 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Quarter ending Jun 2027 | $-0.29 | $-0.29 | $-0.29 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.69 | $-2.15 | $-1.27 | 5 |
| FY 2027 | $-1.79 | $-1.48 | $-0.91 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $50000.00 | $50000.00 | $50000.00 | 3 |
| Quarter ending Dec 2026 | $83333.00 | $83333.00 | $83333.00 | 3 |
| Quarter ending Mar 2027 | $250000.00 | $250000.00 | $250000.00 | 1 |
| Quarter ending Jun 2027 | $300000.00 | $300000.00 | $300000.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $133333.00 | $133333.00 | $133333.00 | 4 |
| FY 2027 | $1.00M | $1.00M | $1.00M | 4 |
